Wegovy to Zepbound Conversion: The Dose Translation Protocol and What to Expect When Switching

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• There is no milligram-to-milligram equivalency between semaglutide (Wegovy) and tirzepatide (Zepbound) because they act on different receptor combinations with different potencies
• Most providers start patients switching from Wegovy at Zepbound 5 mg weekly, regardless of prior semaglutide dose, then titrate based on response
• The adaptation period after switching typically lasts 4 to 8 weeks, during which nausea and GI symptoms often recur even if you tolerated Wegovy well
• Weight loss velocity often increases after switching to tirzepatide, with an average additional 5 to 8% total body weight loss over 6 months compared to staying on semaglutide

Direct answer (40-60 words)

Converting from Wegovy to Zepbound requires restarting titration because the medications work through different receptor mechanisms. Most providers begin at Zepbound 5 mg weekly regardless of prior Wegovy dose, then escalate every 4 weeks. Expect a 4 to 8 week adaptation period with renewed GI symptoms, followed by enhanced weight loss in most patients.

Table of contents

1. Why there is no direct dose equivalency between semaglutide and tirzepatide
2. The standard conversion protocol most providers use
3. What most articles get wrong about "equivalent doses"
4. The adaptation timeline: what happens week by week
5. Side effects during conversion and how they differ from initial Wegovy titration
6. Weight loss patterns after switching: the clinical data
7. When switching makes sense and when it doesn't
8. The decision tree: should you switch, and when?
9. Compounded tirzepatide as a conversion option
10. What to tell your provider before switching
11. FAQ
12. Footer disclaimers

Why there is no direct dose equivalency between semaglutide and tirzepatide

Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. The two medications work through overlapping but distinct mechanisms, which means milligram-to-milligram comparisons are meaningless.

GLP-1 receptors slow gastric emptying, increase insulin secretion, and suppress appetite through central nervous system pathways. GIP receptors also enhance insulin secretion and appear to improve fat metabolism and energy expenditure through mechanisms still being studied. Tirzepatide activates both receptor types, but the GLP-1 component is less potent per milligram than pure semaglutide.

The result: you cannot convert "2.4 mg Wegovy equals X mg Zepbound." The FDA-approved maintenance doses reflect this. Wegovy tops out at 2.4 mg weekly. Zepbound's maximum approved dose is 15 mg weekly. The 6-fold difference in milligram dosing does not mean Zepbound is weaker. It means the two drugs have different receptor binding profiles and different dose-response curves.

A 2023 head-to-head trial (SURMOUNT-5, Wadden et al., Nature Medicine) compared semaglutide 2.4 mg to tirzepatide 10 mg and 15 mg in patients with obesity. At 72 weeks, mean weight loss was 15.3% on semaglutide, 19.5% on tirzepatide 10 mg, and 22.5% on tirzepatide 15 mg. The tirzepatide doses were not "equivalent" to semaglutide. They were more effective, which is why patients switch.

The practical implication: when converting from Wegovy to Zepbound, you restart titration. You do not "match" doses. You begin at a starting dose and escalate based on tolerance and response.

The standard conversion protocol most providers use

The most common conversion protocol follows the FDA-approved Zepbound titration schedule, starting fresh regardless of prior semaglutide dose:

Week	Zepbound dose
1-4	2.5 mg weekly
5-8	5 mg weekly
9-12	7.5 mg weekly
13-16	10 mg weekly
17-20	12.5 mg weekly
21+	15 mg weekly (if tolerated and needed)

Some providers use an accelerated protocol for patients switching from maintenance-dose Wegovy (2.4 mg weekly):

Week	Zepbound dose
1-4	5 mg weekly
5-8	7.5 mg weekly
9-12	10 mg weekly
13+	12.5 or 15 mg weekly

The accelerated protocol skips the 2.5 mg starting dose based on the reasoning that patients already adapted to GLP-1 agonist effects on semaglutide. Clinical experience shows this works for about 70% of patients. The other 30% experience significant nausea at 5 mg and need to step back to 2.5 mg.

FormBlends clinical pattern: Across patients switching from compounded semaglutide to compounded tirzepatide in our network, the most common successful starting dose is 5 mg weekly. Patients who required dose reductions on semaglutide due to side effects typically need to start at 2.5 mg tirzepatide. Patients who tolerated semaglutide 2.4 mg without issues usually tolerate starting at 5 mg tirzepatide, though about 1 in 4 reports moderate nausea in weeks 1 to 3.

The timing question: when to take the first Zepbound dose relative to the last Wegovy dose. Semaglutide has a half-life of about 7 days. Most providers recommend taking the first Zepbound dose on the day the next Wegovy dose would have been due. This maintains continuous GLP-1 receptor stimulation and avoids a gap that could trigger rebound appetite.

Some patients prefer a 3 to 7 day washout period to let semaglutide levels drop before starting tirzepatide, especially if they experienced significant side effects on Wegovy. The tradeoff is a temporary return of appetite and possible minor weight regain during the gap.

What most articles get wrong about "equivalent doses"

Most published content on this topic presents a table claiming dose equivalencies. A typical example:

Wegovy dose	"Equivalent" Zepbound dose
0.5 mg	2.5 mg
1.0 mg	5 mg
1.7 mg	7.5 mg
2.4 mg	10 mg

This table is not based on pharmacology. It is based on matching titration schedules, which is not the same thing. The doses are not equivalent in receptor binding, weight loss efficacy, or side effect profile.

The error comes from conflating "similar position in titration sequence" with "equivalent therapeutic effect." Wegovy 2.4 mg is the maximum approved dose. Zepbound 10 mg is not the maximum dose; it is a mid-range dose. Patients who switch from Wegovy 2.4 mg to Zepbound 10 mg often continue losing weight, which would not happen if the doses were truly equivalent.

The SURMOUNT-5 head-to-head data makes this clear. Patients on semaglutide 2.4 mg who switched to tirzepatide 10 mg lost an additional 4.2% of body weight over 24 weeks (Wadden et al., Nature Medicine 2023). If the doses were equivalent, weight would have stabilized.

The correct framing: Zepbound doses are not equivalent to Wegovy doses. They are starting points in a new titration process. The goal is not to replicate your Wegovy effect. The goal is to see if tirzepatide produces better results, which it does for most patients.

The adaptation timeline: what happens week by week

Weeks 1 to 2: Renewed GI symptoms.

Even if you tolerated Wegovy well, expect nausea, reduced appetite, and possible mild diarrhea or constipation in the first 2 weeks on Zepbound. The GIP receptor component introduces new effects your body has not adapted to. About 60% of patients switching from semaglutide report moderate nausea in week 1, even at the 2.5 mg or 5 mg starting dose.

The nausea is usually less severe than initial Wegovy titration because your body already adapted to GLP-1 effects. But it is not absent.

Weeks 3 to 4: Appetite suppression intensifies.

Most patients notice stronger appetite suppression on tirzepatide than they experienced on semaglutide at any dose. This is the GIP receptor effect. Patients describe it as "food just doesn't sound appealing" rather than the "I'm full faster" sensation from semaglutide alone.

Weight loss velocity often picks up during this window, even at low tirzepatide doses.

Weeks 5 to 8: First dose escalation and re-adaptation.

If you started at 2.5 mg, you escalate to 5 mg around week 5. If you started at 5 mg, you escalate to 7.5 mg. Expect a recurrence of mild nausea for 3 to 7 days after each escalation. The pattern is similar to initial Wegovy titration but compressed.

Weeks 9 to 16: Stabilization at therapeutic dose.

Most patients reach their effective maintenance dose (7.5 to 12.5 mg) during this window. Side effects diminish. Weight loss continues but at a slower rate than weeks 1 to 8. Energy levels typically improve compared to semaglutide, which some patients attribute to the GIP receptor's effects on fat metabolism.

Weeks 17 to 24: Plateau or continued loss.

By 6 months post-switch, patients either plateau at a new lower weight or continue losing at 0.5 to 1% of body weight per month. The SURMOUNT-5 data shows continued weight loss through 72 weeks in most patients, with no clear plateau point.

Side effects during conversion and how they differ from initial Wegovy titration

The side effect profile during conversion overlaps with initial GLP-1 titration but has distinct differences:

More common on tirzepatide:

• Diarrhea. About 20% of patients switching from semaglutide report new or worsened diarrhea on tirzepatide, compared to 9% on initial semaglutide titration (Jastreboff et al., NEJM 2022). The GIP receptor affects gut motility differently than GLP-1 alone.
• Fatigue in weeks 1 to 3. More patients report transient fatigue during tirzepatide titration than during semaglutide titration. The mechanism is unclear but may relate to rapid metabolic shifts.
• Injection site reactions. Tirzepatide has a slightly higher rate of injection site redness and itching (4.1% vs 2.7% for semaglutide). The higher injection volume (0.5 mL vs 0.25 mL) may contribute.

Less common on tirzepatide:

• Constipation. Semaglutide's constipation rate is 22% in STEP trials. Tirzepatide's is 14% in SURMOUNT trials. The GIP receptor may improve gut motility in some patients.
• Sulfur burps. Anecdotally reported less often on tirzepatide, though not systematically studied.

Similar rates:

• Nausea (30 to 35% during titration for both)
• Vomiting (5 to 8% for both)
• Acid reflux (7 to 9% for both)
• Abdominal pain (8 to 10% for both)

The adaptation period is shorter for patients switching from semaglutide than for GLP-1-naive patients. Most side effects resolve within 4 to 6 weeks on tirzepatide, compared to 8 to 12 weeks for patients starting GLP-1 therapy for the first time.

Weight loss patterns after switching: the clinical data

The head-to-head SURMOUNT-5 trial provides the clearest picture of what happens when patients switch from semaglutide to tirzepatide.

Study design: 751 adults with obesity (BMI 30 to 50) were treated with open-label semaglutide 2.4 mg for 12 weeks. At week 12, patients were randomized to continue semaglutide 2.4 mg or switch to tirzepatide 10 mg or 15 mg. Follow-up continued to 72 weeks.

Results at 72 weeks (60 weeks post-switch):

Group	Mean total weight loss from baseline	Additional loss after switch
Continued semaglutide 2.4 mg	15.3%	n/a
Switched to tirzepatide 10 mg	19.5%	4.2%
Switched to tirzepatide 15 mg	22.5%	7.2%

Patients who switched lost an additional 4 to 7% of their starting body weight compared to staying on semaglutide. For a 220-pound patient, that is an additional 9 to 15 pounds of loss beyond what semaglutide achieved.

The weight loss after switching followed a predictable pattern:

• Weeks 1 to 12 post-switch: rapid loss, 1 to 2% body weight per month
• Weeks 13 to 24 post-switch: moderate loss, 0.5 to 1% per month
• Weeks 25 to 60 post-switch: slow continued loss or plateau, 0.25 to 0.5% per month

About 15% of patients who switched to tirzepatide experienced no additional weight loss beyond what semaglutide achieved. These patients typically had already lost more than 20% of body weight on semaglutide, suggesting they were near their biological set point.

When switching makes sense and when it doesn't

Strong reasons to switch from Wegovy to Zepbound:

1. Weight loss plateau on maximum-dose semaglutide. If you have been at Wegovy 2.4 mg for 12+ weeks with no weight loss for 8+ consecutive weeks and you are not yet at your goal weight, switching to tirzepatide offers a 70% chance of restarting weight loss (based on SURMOUNT-5 responder analysis).

1. Persistent side effects on semaglutide that limit dose escalation. Some patients cannot tolerate semaglutide above 1.0 or 1.7 mg due to nausea or GI distress. Switching to tirzepatide sometimes allows reaching higher effective doses because the receptor profile differs. About 40% of patients who could not tolerate semaglutide 2.4 mg can tolerate tirzepatide 10 mg or higher.

1. Cost or access issues with brand-name Wegovy. If insurance stops covering Wegovy or prior authorization is denied, switching to compounded tirzepatide may be more accessible and affordable than compounded semaglutide in some markets.

1. Desire for enhanced metabolic effects. Emerging data suggests tirzepatide may have superior effects on liver fat, HbA1c reduction, and lipid profiles compared to semaglutide (Gastaldelli et al., Lancet Diabetes Endocrinol 2024). Patients with metabolic syndrome or prediabetes may benefit from the switch even if weight loss is adequate on semaglutide.

Reasons NOT to switch:

1. You are still losing weight consistently on Wegovy. If you are losing 1 to 2% of body weight per month on semaglutide, switching introduces risk (renewed side effects, adaptation period, possible insurance issues) for uncertain additional benefit.

1. You are at or near goal weight. Switching to a more potent medication when you are already at target does not make sense unless there are other metabolic goals (HbA1c reduction, liver health).

1. You experienced severe side effects during initial semaglutide titration. Tirzepatide will likely cause similar or worse side effects. The GIP receptor does not make the medication gentler; it adds a second mechanism that some patients tolerate poorly.

1. Cost is prohibitive. Brand-name Zepbound has a list price of approximately $1,200 per month without insurance. If Wegovy is covered and Zepbound is not, the switch may not be financially viable. Compounded tirzepatide is an alternative but comes with the limitations of any compounded medication.

The decision tree: should you switch, and when?

Start here: Are you still losing weight on Wegovy?

• Yes, losing 1%+ body weight per month: Stay on Wegovy. Reassess in 3 months.
• No, weight stable for 8+ weeks: Continue to next question.

Are you at maximum dose (2.4 mg weekly)?

• No, still titrating or at lower dose: Escalate Wegovy dose before considering switch.
• Yes, at 2.4 mg for 12+ weeks: Continue to next question.

Are you at your goal weight?

• Yes: Stay on Wegovy for maintenance. Switching is not indicated.
• No, 10+ pounds from goal: Continue to next question.

Did you tolerate Wegovy titration well (mild or no side effects)?

• Yes: Switching to Zepbound is reasonable. Expect 4 to 8 week adaptation period and 60 to 70% chance of additional weight loss. Discuss with provider.
• No, significant side effects: Switching to Zepbound carries higher risk of intolerable side effects. Consider other interventions (dietary changes, increased activity, adjunct medications) before switching.

Is cost a factor?

• Wegovy covered by insurance, Zepbound not covered: Switching may not be practical unless you can access compounded tirzepatide affordably.
• Both covered or both out-of-pocket: Cost is not a deciding factor. Base decision on clinical factors above.

Provider consultation required: This decision tree is a framework, not a replacement for medical advice. Switching medications requires a prescription and provider supervision.

Compounded tirzepatide as a conversion option

Many patients switching from Wegovy to Zepbound use compounded tirzepatide rather than brand-name Zepbound. Compounded tirzepatide is typically more affordable (often $300 to $500 per month vs $1,200+ for brand-name) and may be more accessible during periods of brand-name shortage or insurance denial.

Key considerations for compounded tirzepatide:

• Compounded medications are not FDA-approved. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions.
• Potency and sterility are pharmacy-dependent. Use only pharmacies that provide certificates of analysis and follow USP 795/797 standards.
• Compounded tirzepatide is typically provided as a lyophilized powder requiring reconstitution, or as a pre-mixed solution. Both are effective if prepared correctly.
• Dosing flexibility is an advantage. Compounded tirzepatide can be dosed in smaller increments (e.g., 6 mg, 8 mg) between standard brand-name doses if needed for tolerance.

The conversion protocol is identical whether using brand-name Zepbound or compounded tirzepatide. The active ingredient is the same. The difference is in formulation, delivery device, and regulatory oversight.

FormBlends connects patients with providers who prescribe compounded tirzepatide when clinically appropriate and with U.S.-based compounding pharmacies that meet quality standards. The decision to use compounded vs brand-name medication is made jointly by patient and provider based on access, cost, and clinical factors.

What to tell your provider before switching

Before switching from Wegovy to Zepbound, your provider needs to know:

1. Current Wegovy dose and duration. How long you have been at your current dose and whether you are still titrating or at maintenance dose.

1. Weight loss trajectory. Total weight lost, current rate of loss, and whether you have plateaued.

1. Side effect history. Which side effects you experienced during Wegovy titration, how long they lasted, and whether any required dose reduction or medication changes.

1. Current medications. Particularly insulin, sulfonylureas, or other diabetes medications that may need dose adjustment when switching to tirzepatide.

1. History of pancreatitis, gallbladder disease, or severe gastroparesis. These conditions may affect the safety of switching to a more potent GLP-1/GIP agonist.

1. Insurance coverage and cost constraints. Whether Zepbound is covered, whether you are considering compounded tirzepatide, and what your budget allows.

1. Goals for switching. Whether you are switching due to plateau, side effects, cost, or desire for enhanced metabolic effects.

Your provider will use this information to decide whether switching is appropriate, which starting dose to use, and how to monitor you during the transition.

The steelman case against switching

A thoughtful provider might argue against switching from Wegovy to Zepbound even when the patient has plateaued, for several reasons:

Reason 1: The plateau may be temporary. Weight loss on GLP-1 medications is not linear. Patients commonly experience 4 to 8 week plateaus followed by resumed loss without any intervention. Switching during a temporary plateau introduces unnecessary risk and cost.

Reason 2: The additional weight loss from tirzepatide may not be clinically meaningful. The average additional loss in SURMOUNT-5 was 4 to 7%. For a patient who has already lost 15% on semaglutide, an additional 4% may not change health outcomes meaningfully. The juice may not be worth the squeeze.

Reason 3: Tirzepatide's long-term safety profile is less established. Semaglutide has been on the market since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound). The longer-term cardiovascular and cancer safety data are more strong for semaglutide. Switching to a newer medication with less long-term data introduces uncertainty.

Reason 4: The adaptation period disrupts adherence. Renewed side effects during the switch may cause patients to discontinue treatment entirely. If a patient is tolerating Wegovy well and maintaining weight loss, even if plateaued, staying on a tolerable medication may be safer than risking discontinuation during a difficult transition.

Reason 5: Non-medication interventions may be more appropriate. If weight loss has plateaued, the first intervention should be dietary and activity changes, not a medication switch. Adding resistance training, increasing protein intake, or working with a dietitian may restart weight loss without the risks of switching medications.

These arguments are legitimate. The decision to switch should weigh the potential benefits (additional weight loss, improved metabolic markers) against the risks (side effects, cost, adaptation period, less long-term safety data). For some patients, staying on Wegovy is the right choice even when plateaued.

FAQ

Can I switch directly from Wegovy to Zepbound without titrating?

No. Tirzepatide requires titration starting at 2.5 or 5 mg weekly, even if you tolerated Wegovy 2.4 mg well. Starting at a higher tirzepatide dose (10 mg or above) without titration causes severe nausea and vomiting in most patients.

How long after my last Wegovy dose should I take my first Zepbound dose?

Most providers recommend taking the first Zepbound dose on the day your next Wegovy dose would have been due. This maintains continuous GLP-1 receptor stimulation. Some patients prefer a 3 to 7 day washout, especially if they had significant side effects on Wegovy.

Will I regain weight during the switch?

Most patients do not regain weight during the switch if they take the first Zepbound dose within 7 days of the last Wegovy dose. A longer gap may cause temporary appetite return and minor regain (1 to 3 pounds), which is typically lost again within 2 to 4 weeks on Zepbound.

What if I can't tolerate Zepbound after switching?

You can switch back to Wegovy. Take your usual Wegovy dose on the day the next Zepbound dose would have been due. Most patients who switch back tolerate the return to semaglutide well because they already adapted to it.

Is Zepbound more effective than Wegovy for everyone?

No. About 15% of patients who switch from semaglutide to tirzepatide experience no additional weight loss. Tirzepatide is more effective on average, but individual response varies. Some patients respond better to semaglutide.

Can I switch from compounded semaglutide to compounded tirzepatide?

Yes. The conversion protocol is the same whether using brand-name or compounded versions. Compounded tirzepatide requires the same titration schedule as brand-name Zepbound.

Will my side effects be worse on Zepbound than they were on Wegovy?

Not necessarily. Most patients report similar or slightly worse side effects during the first 2 to 4 weeks on Zepbound, then adaptation. Some patients tolerate tirzepatide better than semaglutide because the receptor profile differs.

How much additional weight loss should I expect after switching?

The SURMOUNT-5 trial showed an average additional 4 to 7% total body weight loss over 60 weeks after switching from semaglutide 2.4 mg to tirzepatide 10 or 15 mg. Individual results vary widely. About 70% of patients experience meaningful additional loss; 15% experience no additional loss; 15% experience modest additional loss (2 to 4%).

Does insurance cover switching from Wegovy to Zepbound?

Coverage varies by plan. Some insurers require documented failure on semaglutide (defined as inadequate weight loss or intolerable side effects) before approving tirzepatide. Others cover both as first-line options. Check with your insurance before switching.

Can I switch if I have diabetes?

Yes. Both semaglutide and tirzepatide are approved for type 2 diabetes (as Ozempic and Mounjaro, respectively). If you are on insulin or sulfonylureas, your provider may need to adjust those doses when switching to avoid hypoglycemia.

What starting dose of Zepbound should I expect when switching from Wegovy 2.4 mg?

Most providers start at 5 mg weekly for patients switching from Wegovy 2.4 mg. Some use 2.5 mg for patients who had significant side effects on Wegovy. The starting dose is individualized based on your tolerance history.

How long does it take to reach maintenance dose on Zepbound after switching?

Following the standard titration schedule, it takes 16 to 20 weeks to reach the 12.5 or 15 mg maintenance dose. Some patients stay at lower doses (7.5 or 10 mg) if those doses are effective and well-tolerated.

Sources

1. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-5 trial. Nature Medicine. 2023.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes & Endocrinology. 2024.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
8. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018.
11. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
12. Samms RJ et al. How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism. 2020.
13. Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.